Profound Medical (PROF) EBITDA (2024 - 2026)

Profound Medical's EBITDA history runs 3 years deep, the most recent figure standing at -$8.1 million for Q1 2026.

• In Q1 2026, EBITDA rose 24.13% year-over-year to -$8.1 million; the TTM figure through Mar 2026 stood at -$37.7 million (down 11.92% YoY), while the FY2025 annual figure was -$40.3 million, down 31.49% from the prior year.
• EBITDA was -$8.1 million for Q1 2026 at Profound Medical, down from -$7.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$6.9 million in Q4 2024 to a low of -$13.0 million in Q2 2025.
• Historically, EBITDA has averaged -$8.8 million across 3 years, with a median of -$8.1 million in 2026.
• The sharpest annual moves came in 2025 and 2026: EBITDA sank 75.69% in 2025, then climbed 24.13% in 2026.
• A 3-year view of EBITDA shows it stood at -$6.9 million in 2024, then dropped by 14.24% to -$7.9 million in 2025, then dropped by 2.0% to -$8.1 million in 2026.
• The last three EBITDA figures came in at -$8.1 million (Q1 2026), -$7.9 million (Q4 2025), and -$8.8 million (Q3 2025), per Business Quant data.